Breast cancer is the most diagnosed cancer in women and the second leading cause of cancer-related mortality worldwide. Advances in genetic technology have highlighted the heterogeneity of breast cancer, composed of various biological subtypes, with genetic profiling playing a crucial role in predicting chemotherapy response. This underscores the importance of identifying sensitive diagnostic and prognostic markers for early detection and developing more efficient targeted therapies. Among these, survivin, a protein linked to apoptosis inhibition and cell cycle regulation, is strongly expressed in various cancers, including breast cancer, where its overexpression is associated with poor prognosis and reduced survival rates. To analyze the effects of survivin gene inhibition in a triple-negative breast cancer (TNBC) model. The MDA-MB-231 cell line was stably transfected with short hairpin RNA targeting survivin, and the inhibition was validated via RT-qPCR and Western blot. Morphological evaluation, proliferation and migration assays, and a differential gene expression analysis using the GeneChip™ Human Gene 2.0 ST Array were performed. Statistical analyses were conducted with GraphPad Prism version 8 and Transcriptome Analysis Console. Survivin-inhibited MDA-MB-231-KD cells exhibited evident morphological changes, reduced migration capacity, and altered expression of genes such as BCL2, COX1, COX2, VGF, BIR2, and CDC20, involved in key cancer signaling pathways. Inhibition of survivin in this TNBC model induces critical cellular changes and significantly alters gene expression associated with tumor progression, highlighting its potential as a therapeutic target.
AcharyaR. The recent progresses in ShRNA-Nanoparticle conjugate as a therapeutic approach. Mater Sci Eng C Mater Biol Appl, 2019; 104:109928; doi: 10.1016/J.MSEC.2019.109928
2.
AdinewGM, MessehaS, TakaE, et al.The prognostic and therapeutic implications of the chemoresistance gene BIRC5 in triple-negative breast cancer. Cancers (Basel), 2022; 14(21):5180; doi: 10.3390/CANCERS14215180
3.
AhmadzadaT, ReidG, McKenzieDR. Fundamentals of SiRNA and MiRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer. Biophys Rev, 2018; 10(1):69–86; doi: 10.1007/S12551-017-0392-1
4.
AlmansourNM, BatinA, Al BatinH, et al.Triple-negative breast cancer: A brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence. Front Mol Biosci, 2022; 9:836417; doi: 10.3389/FMOLB.2022.836417
5.
Al-YahyaS, Al-SaifM, Al-GhamdiM, et al.Post-transcriptional regulation of BIRC5/survivin expression and induction of apoptosis in breast cancer cells by tristetraprolin. RNA Biol, 2024; 21(1):1–15; doi: 10.1080/15476286.2023.2286101
6.
AmpeC, WitjesL, Van TroysM. Cancer type-specific alterations in actin genes: Worth a closer look? Int Rev Cell Mol Biol, 2021; 360:133–184; doi: 10.1016/BS.IRCMB.2021.02.017
7.
Baghal-SadriforoushS, BagheriM, RadIA, et al.PI3K inhibition sensitize the cisplatin-resistant human ovarian cancer cell OVCAR3 by induction of oxidative stress. Rep Biochem Mol Biol, 2022; 10(4):675–685; doi: 10.52547/RBMB.10.4.675
8.
BarnesN, HaywoodP, FlintP, et al.Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer, 2006; 94(2):253–258; doi: 10.1038/SJ.BJC.6602932
9.
BergerA, QuastSA, PlötzM, et al.Sensitization of melanoma cells for TRAIL-induced apoptosis by BMS-345541 correlates with altered phosphorylation and activation of bax. Cell Death Dis, 2013; 4(1):e477–e477; doi: 10.1038/cddis.2012.198
10.
Board PCGE. Genetics of Breast and Gynecologic Cancers (PDQ®). PDQ Cancer Information Summaries; 2024.
11.
CampbellKJ, TaitSWG. Targeting BCL-2 regulated apoptosis in cancer. Open Biol, 2018; 8(5):180002; doi: 10.1098/RSOB.180002
12.
CánovasPM. Survivin mediates mitotic onset in HeLa cells through activation of the Cdk1-Cdc25B axis. Res Sq, 2024; doi: 10.21203/RS.3.RS-3949429/V1
13.
CarrascoRA, StammNB, MarcussonE, et al.Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther, 2011; 10(2):221–232; doi: 10.1158/1535-7163.MCT-10-0756
14.
ChongZX, YeapSK, HoWY. Transfection types, methods and strategies: A technical review. PeerJ, 2021; 9:e11165; doi: 10.7717/peerj.11165
15.
DassSA, TanKL, RajanRS, et al.Triple negative breast cancer: A review of present and future diagnostic modalities. Medicina (Kaunas), 2021; 57(1):62; doi: 10.3390/MEDICINA57010062
16.
Fäldt BedingA, LarssonP, HelouK, et al.Pan-cancer analysis identifies BIRC5 as a prognostic biomarker. BMC Cancer, 2022; 22(1):322; doi: 10.1186/S12885-022-09371-0
17.
FalkeK, SchröderE, MoselS, et al.Old passengers as new drivers: Chromosomal passenger proteins engage in translesion synthesis. Cells, 2024; 13(21):1804; doi: 10.3390/cells13211804
18.
FanY, PanY, JiaL, et al.BIRC5 facilitates cisplatin-chemoresistance in a M6A-dependent manner in ovarian cancer. Cancer Med, 2024; 13(1):e6811; doi: 10.1002/CAM4.6811
19.
FoutadakisS, KordiasD, VatsellasG, et al.Identification of new chemoresistance-associated genes in triple-negative breast cancer by single-cell transcriptomic analysis. Int J Mol Sci, 2024; 25(13):6853; doi: 10.3390/ijms25136853
20.
GuY, TangS, WangZ, et al.A pan-cancer analysis of the prognostic and immunological role of β-actin (ACTB) in human cancers. Bioengineered, 2021; 12(1):6166–6185; doi: 10.1080/21655979.2021.1973220
21.
HafeziS, RahmaniM. Targeting BCL-2 in cancer: Advances, challenges, and perspectives. Cancers (Basel), 2021; 13(6):1292; doi: 10.3390/CANCERS13061292
22.
HamiltonAM, WalensA, Van AlstenSC, et al.BIRC5 expression by race, age and clinical factors in breast cancer patients. Breast Cancer Res, 2024; 26(1):50; doi: 10.1186/s13058-024-01792-y
23.
HamyAS, BiecheI, Lehmann-CheJ, et al.BIRC5 (survivin): A pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy. Breast Cancer Res Treat, 2016; 159(3):499–511; doi: 10.1007/S10549-016-3961-2
24.
Hashemi GoradelN, NajafiM, SalehiE, et al.Cyclooxygenase-2 in cancer: A review. J Cell Physiol, 2019; 234(5):5683–5699; doi: 10.1002/JCP.27411
25.
HuB, ZhongL, WengY, et al.Therapeutic SiRNA: State of the art. Signal Transduct Target Ther, 2020; 5(1):101–125; doi: 10.1038/s41392-020-0207-x
26.
KonturekPC, RembiaszK, BurnatG, et al.Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer. Dig Dis Sci, 2006; 51(4):779–787; doi: 10.1007/s10620-006-3206-z
27.
KumarH, GuptaNV, JainR, et al.A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer. J Adv Res, 2023; 54:271–292; doi: 10.1016/J.JARE.2023.02.005
28.
LewisKD, SamlowskiW, WardJ, et al.A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs, 2011; 29(1):161–166; doi: 10.1007/s10637-009-9333-6
29.
LiF, AljahdaliI, LingX. Cancer therapeutics using survivin BIRC5 as a target: What can we do after over two decades of study? J Exp Clin Cancer Res, 2019; 38(1):368; doi: 10.1186/S13046-019-1362-1
30.
LiG, WangY, WangW, et al.BIRC5 as a prognostic and diagnostic biomarker in pan-cancer: An integrated analysis of expression, immune subtypes, and functional networks. Front Genet, 2024; 15:1509342; doi: 10.3389/FGENE.2024.1509342
31.
LiangJ, ZhaoW, TongP, et al.Comprehensive molecular characterization of inhibitors of apoptosis proteins (IAPs) for therapeutic targeting in cancer. BMC Med Genomics, 2020; 13(1):7–13; doi: 10.1186/s12920-020-0661-x
32.
LivakKJ, SchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods, 2001; 25(4):402–408; doi: 10.1006/meth.2001.1262
33.
LuoX, O’NeillKL, HuangK. The third model of bax/bak activation: a bcl-2 family feud finally resolved? F1000Res, 2020; 9:F1000 Faculty Rev–F1000 Faculty 935; doi: 10.12688/f1000research.25607.1
34.
NakaharaT, TakeuchiM, KinoyamaI, et al.YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res, 2007; 67(17):8014–8021; doi: 10.1158/0008-5472.CAN-07-1343
35.
OparinaN, ErlandssonMC, BedingAF, et al.Prognostic significance of BIRC5/survivin in breast cancer: Results from three independent cohorts. Cancers (Basel), 2021; 13(9):2209; doi: 10.3390/CANCERS13092209
36.
PalS, PradhanS, NarayanG, et al.Change in expression of biomarkers bcl-2 and survivin in patients of cancer cervix undergoing chemo-radiotherapy. Int J Radiat Oncol*Biol*Phys, 2020; 108(3):e455; doi: 10.1016/j.ijrobp.2020.07.2566
37.
QianS, WeiZ, YangW, et al.The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol, 2022; 12:985363; doi: 10.3389/FONC.2022.985363
Raynaud-MessinaB, MazzoliniL, MoisandAet al.Elongation of centriolar microtubule triplets contributes to the formation of the mitotic spindle in gamma-tubulin-depleted cells. J Cell Sci, 2004; 117(Pt 23):5497–5507; doi: 10.1242/jcs.01401
40.
RichterC, MayhewD, RennhackJP, et al.Genomic amplification and functional dependency of the gamma actin gene ACTG1 in uterine cancer. Int J Mol Sci, 2020; 21(22):8690; doi: 10.3390/IJMS21228690
41.
SatohT, OkamotoI, MiyazakiM, et al.Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res, 2009; 15(11):3872–3880; doi: 10.1158/1078-0432.CCR-08-1946
42.
ShanS, SuM, WangH, et al.Y-27632 targeting ROCK1&2 modulates cell growth, fibrosis and epithelial-mesenchymal transition in hyperplastic prostate by inhibiting β-catenin pathway. Mol Biomed, 2024; 5(1):52; doi: 10.1186/s43556-024-00216-9
43.
ShangX, LiuG, ZhangY, et al.Downregulation of BIRC5 inhibits the migration and invasion of esophageal cancer cells by interacting with the PI3K/akt signaling pathway. Oncol Lett, 2018; 16(3):3373–3379; doi: 10.3892/OL.2018.8986
44.
SlomovitzBM, ColemanRL. The PI3K/AKT/MTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res, 2012; 18(21):5856–5864; doi: 10.1158/1078-0432.CCR-12-0662
45.
SungH, FerlayJ, SiegelRL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021; 71(3):209–249; doi: 10.3322/CAAC.21660
46.
UrenAG, WongL, PakuschM, et al.Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol, 2000; 10(21):1319–1328; doi: 10.1016/S0960-9822(00)00769-7
47.
WangEJY, ChenIH, KuoBYT, et al.Alterations of cytoskeleton networks in cell fate determination and cancer development. Biomolecules, 2022; 12(12):1862; doi: 10.3390/BIOM12121862
48.
WangQ, GreeneMI. Survivin as a therapeutic target for the treatment of human cancer. Cancers (Basel), 2024; 16(9):1705; doi: 10.3390/cancers16091705
49.
WarrierNM, AgarwalP, KumarP. Emerging importance of survivin in stem cells and cancer: The development of new cancer therapeutics. Stem Cell Rev Rep, 2020; 16(5):828–852; doi: 10.1007/S12015-020-09995-4
50.
WheatleySP, AltieriDC. Survivin at a glance. J Cell Sci, 2019; 132(7):jcs223826; doi: 10.1242/jcs.223826
51.
XiaoL, PengH, YanM, et al.Silencing ACTG1 expression induces prostate cancer epithelial mesenchymal transition through MAPK/ERK signaling pathway. DNA Cell Biol, 2021; 40(11):1445–1455; doi: 10.1089/DNA.2021.0416
52.
ZakariaN, YusoffNM, ZakariaZ, et al.Inhibition of NF-ΚB signaling reduces the stemness characteristics of lung cancer stem cells. Front Oncol, 2018; 8(MAY):166; doi: 10.3389/fonc.2018.00166
53.
ZhangH, ZhengT, QinC, et al.CCT6A promotes cell proliferation in Colon cancer by targeting BIRC5 associated with P53 status. Cancer Gene Ther, 2024; 31(8):1151–1163; doi: 10.1038/s41417-024-00806-3
54.
ZhangM, ZhangX, ZhaoS, et al.Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients. Target Oncol, 2014; 9(4):349–357; doi: 10.1007/S11523-013-0300-Y
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
